World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
130
Citations
57053
World Ranking
2506
National Ranking
1412

David M. Gershenson publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where David M. Gershenson sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 671 publications — 78th percentile

78% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

David M. Gershenson D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where David M. Gershenson sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 130 D-Index — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

David M. Gershenson is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research focuses primarily on medical fields related to reproductive health and oncology, with a significant emphasis on ovarian cancer diagnosis and treatment.

The main fields of study for this scientist include Medicine, with notable subfields in Reproductive Medicine, Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, and Obstetrics and Gynecology.

Their research topics cover a variety of cancer-related subjects, including:

  • Ovarian cancer diagnosis and treatment
  • Endometrial and Cervical Cancer Treatments
  • Intraperitoneal and Appendiceal Malignancies
  • Renal cell carcinoma treatment
  • Cancer Mechanisms and Therapy
  • PARP inhibition in cancer therapy
  • Cancer Genomics and Diagnostics

Frequent coauthors in their publications are:

  • Shannon N. Westin
  • Anil K. Sood
  • R. Tyler Hillman
  • Robert L. Coleman
  • Lauren Cobb

Their work has been published frequently in the following venues:

  • Gynecologic Oncology
  • International Journal of Gynecological Cancer
  • Journal of Clinical Oncology
  • Cancer Research
  • Clinical Cancer Research

Recent papers authored or coauthored by David M. Gershenson include:

  • Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology, 2021, Journal of the National Comprehensive Cancer Network
  • NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022, 2022, Journal of the National Comprehensive Cancer Network
  • MEK inhibitor resistance mechanisms and recent developments in combination trials, 2020, Cancer Treatment Reviews
  • Low-grade serous ovarian cancer: State of the science, 2020, Gynecologic Oncology
  • EFFORT: EFFicacy Of adavosertib in parp ResisTance: A randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer., 2021, Journal of Clinical Oncology

Best Publications

  • Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.

    Mitchell Morris;Patricia J. Eifel;Jiandong Lu;Perry W. Grigsby

  • Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma

    Premal H Thaker;Liz Y Han;Aparna A Kamat;Jesusa M Arevalo

  • Pelvic Irradiation With Concurrent Chemotherapy Versus Pelvic and Para-Aortic Irradiation for High-Risk Cervical Cancer: An Update of Radiation Therapy Oncology Group Trial (RTOG) 90-01

    Patricia J Eifel;Kathryn Winter;Mitchell Morris;Charles F Levenback

  • Prophylactic Surgery to Reduce the Risk of Gynecologic Cancers in the Lynch Syndrome

    Kathleen M. Schmeler;Henry T. Lynch;Lee-May Chen;Mark F. Munsell

  • Grading ovarian serous carcinoma using a two-tier system.

    Anais Malpica;Michael T. Deavers;Karen Lu;Diane C. Bodurka

  • Ovarian Cancer: Screening, Treatment, and Follow-up

    Vicki Seltzer;Bruce H. Drukker;Brenda W. Gillespie;Lynn M. Gossfeld

  • Stress hormone-mediated invasion of ovarian cancer cells.

    Anil K. Sood;Robert Bhatty;Aparna A. Kamat;Charles N. Landen

  • Selection of Potential Markers for Epithelial Ovarian Cancer with Gene Expression Arrays and Recursive Descent Partition Analysis

    Karen H. Lu;Andrea P. Patterson;Lin Wang;Rebecca T. Marquez

  • Quality of Life and Sexual Functioning in Cervical Cancer Survivors

    Michael Frumovitz;Charlotte C Sun;Leslie R. Schover;Mark F. Munsell

  • Curcumin Inhibits Tumor Growth and Angiogenesis in Ovarian Carcinoma by Targeting the Nuclear Factor-κB Pathway

    Yvonne G. Lin;Ajaikumar B. Kunnumakkara;Asha Nair;William M. Merritt

  • Ovarian cancer, version 2.2020

    Deborah K. Armstrong;Ronald D. Alvarez;Jamie N. Bakkum-Gamez;Lisa Barroilhet

  • Intraabdominal lymphatic mapping to direct selective pelvic and paraaortic lymphadenectomy in women with high-risk endometrial cancer: Results of a pilot study

    Thomas W. Burke;Charles Levenback;Carmen Tornos;Mitchell Morris

  • Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer

    Charles N. Landen;Blake Goodman;Ashwini A. Katre;Adam D. Steg;Adam D. Steg

  • Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome.

    Karen H. Lu;Mai Dinh;Wendy Kohlmann;Patrice Watson

  • Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

    John Farley;William E Brady;Vinod Vathipadiekal;Heather A Lankes

  • Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases.

    Brian M Slomovitz;Thomas W Burke;Patricia J Eifel;Lois M Ramondetta

  • Depression, anxiety, and quality of life in patients with epithelial ovarian cancer.

    Diane Bodurka-Bevers;Karen Basen-Engquist;Cindy L. Carmack;Mary A. Fitzgerald

  • Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.

    Tomas Bonome;Ji Young Lee;Dong Choon Park;Mike Radonovich

  • Risk Factors for Young Premenopausal Women With Endometrial Cancer

    Pamela T. Soliman;Jonathan C. Oh;Kathleen M. Schmeler;Charlotte C. Sun

  • Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy

    Jyotsnabaran Halder;Aparna A. Kamat;Charles N. Landen;Liz Y. Han

Frequent Co-Authors

Karen H. Lu
Karen H. Lu The University of Texas MD Anderson Cancer Center
Anil K. Sood
Anil K. Sood The University of Texas MD Anderson Cancer Center
Elvio G. Silva
Elvio G. Silva The University of Texas MD Anderson Cancer Center
Robert L. Coleman
Robert L. Coleman The University of Texas MD Anderson Cancer Center
Michael T. Deavers
Michael T. Deavers Houston Methodist
Anais Malpica
Anais Malpica The University of Texas MD Anderson Cancer Center
John J. Kavanagh
John J. Kavanagh The University of Texas MD Anderson Cancer Center
Robert C. Bast
Robert C. Bast The University of Texas MD Anderson Cancer Center
Russell Broaddus
Russell Broaddus University of North Carolina at Chapel Hill
Patricia J. Eifel
Patricia J. Eifel The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative online degrees in healthcare can open various doors for those interested in medicine. For nursing professionals aiming to advance academically, consider phd nursing programs online, which offer flexible learning schedules and the chance to lead in clinical research or education.

Many registered nurses look to earn higher credentials through an rn to bsn online program—these bridge programs are designed with working professionals in mind and can help increase earning potential and job opportunities.

If you hold a non-nursing bachelor’s degree but want to pivot into nursing, accelerated options like online direct entry msn programs let you fast-track your pathway to advanced nursing roles.

For those concerned about admissions, there are also easy nursing schools to get into that offer a supportive entry into the healthcare workforce. These diverse pathways ensure flexible entry points for aspiring healthcare professionals.

Best Scientists Citing David M. Gershenson

Trending Scientists

Recently Published Articles